Top
Topic: SGLT-2 Inhibitors: A New Approach for Heart Failure Therapy

A special issue of Vessel Plus

ISSN 2574-1209 (Online)

Submission deadline: 30 Sep 2020

Guest Editor(s)

  • Prof. Wilbert S. Aronow, MD, FACC, FAHA
    Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA.

    Website | E-mail

Special Issue Introduction

SGLT2 inhibitors reduce in patients with type 2 diabetes mellitus major adverse cardiovascular events and progression of chronic kidney disease. These drugs also reduce heart failure and cardiovascular death in patients with heart failure and reduced left ventricular ejection fraction. A meta-analysis demonstrated that SGLT2 inhibitors decrease the risk of heart failure hospitalization by 32%, cardiovascular death by 17%, and all-cause mortality by 15%. Ongoing clinical trials are investigating the use of SGLT2 inhibitors in the treatment of patients with and without diabetes mellitus heart failure and preserved left ventricular ejection fraction, heart failure and reduced left ventricular ejection fraction, and chronic kidney disease.

Keywords

SGLT2 inhibitors; empagliflozin; canagliflozin; dapagliflozin; diabetes mellitus; heart failure; chronic kidney disease

Submission Deadline

30 Sep 2020

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://vpjournal.net/pages/view/author_instructions
For Online Submission, please login at http://www.oaemesas.com/vp
Submission Deadline: 30 Sep 2020
Contacts: Mavis Wei, Managing Editor, mavis@vpjournal.net

Published Articles

This special issue is now open for submission.